ResultsIQ

ResultsIQ › Latest results › Nephrocare Health Services Limited

Nephrocare Health Services Limited Q1 FY27 results press release summary

NSE: NEPHROPLUS · BSE: 544647

Results press release of 11 Aug 2026, summarised by AI from the filing.

NephroPlus Q1FY27 revenue ₹281.8 cr, up 23.7% YoY, with Adjusted PAT ₹36.8 cr, up 41.7% YoY.

Key takeaways

  1. Adj. PAT Q1FY27 Adjusted PAT ₹36.8 cr, up 41.7% YoY (Q1FY26: ₹26.0 cr).
  2. Adj. EBITDA margin Expanded 120 bps YoY to 23.1% (Q1FY26: 21.9%) and improved 220 bps sequentially over Q4FY26 (20.9%).
  3. Network Reached 550 operating clinics across 5 countries, with a 50-clinic milestone in the Philippines.

Original filing on BSE

Nephrocare Health Services Limited Q1 FY27 results

As filed: Revenue ₹282 cr, EBITDA ₹63.9 cr, PAT ₹32.0 cr, EBITDA margin 22.7%.

Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹282 cr). Scored once a year-earlier consolidated quarter exists.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹266 cr, EBITDA ₹53.8 cr, PAT ₹30.4 cr, EBITDA margin 20.2%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹266 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: +11.3% in 30 days (Nifty 500: +3.0%).
  • Q3 FY26: Revenue ₹260 cr, EBITDA ₹60.9 cr, PAT ₹32.2 cr, EBITDA margin 23.4%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹260 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: +4.5% in 30 days (Nifty 500: −7.8%).

Past price moves after results do not indicate future moves. Not a recommendation.

Nephrocare Health Services Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.